Flamel Technologies is a drug delivery company with expertise in polymer chemistry.
The company was founded in 1990.
In 1996, Flamel Technologies
(FLML)
became the second French biotech company to enter
the Nasdaq.
The Company has assembled a strong team of researchers
expert in polymer science and biochemistry, and owns cGMP pharmaceutical production
facility of over 100,000 square feet located in Pessac, France (with an annual production capacity of 2 billion tablets or
capsules).
Flamel’s drug delivery platforms,
Medusa®
for therapeutic proteins and peptides, and
Micropump® for
small molecules
, have been developed to improve the therapeutic characteristics,
safety profile and ease of use of wide variety of drugs.
The Company is a recognized world leader in the innovation of delivery systems for
small molecule and protein drugs, providing tailored solutions to the biotech and
pharmaceutical industries for optimized controlled-release delivery of drugs.
Flamel is turning already-marketed or new drugs into more effective and safer
medicines for itself and for its partners.
Flamel has partnership agreements
with major pharmaceutical companies.
The Company is actively seeking partnership agreements for the development and
commercialization of products currently in its pipeline as well as for new products
using Flamel’s proprietary delivery systems.
Flamel Technologies Presentation - August 6, 2008
To view the latest presentation, click here.
Second Quarter 2008 Earnings Announcement:
Flamel released its earnings announcement for the second quarter on August 6th after the market close.
A conference call to discuss these results is scheduled for 8:30 AM (EDT) August 07, 2008.
The dial-in number is (1) 800-374-1498.
International callers are invited to dial-in (1) 706-634-7261. The Conference ID number is 57373983.
Conference Call Webcast
press release
On April 25, 2008, Flamel Technologies announced the presentation of results
of two week study of interferon alpha XL at the European Association for the Study of the Liver.
Click here to access the presentation entitled "Antiviral activity
and tolerance of a novel interferon-alpha-2b sustained release(IFN-alpha-2bXL) compared to Peg-IFN-alpha-2b:a phase Ib trial in
HCV patients".
|